Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder

The effect of treatment as usual on major depressive disorder: A meta-analysis

(2017) Spyros Kolovos et al.   JOURNAL OF AFFECTIVE DISORDERS

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2017) Theo Vos et al.   LANCET

Backing into the future: pharmacological approaches to the management of resistant depression

(2017) P. J. Cowen   PSYCHOLOGICAL MEDICINE

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

(2016) Sidney H. Kennedy et al.   CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE

Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants

(2016) Robert M. Berman et al.   CNS SPECTRUMS

Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial

(2015) Eric J Lenze et al.   LANCET

Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: A subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter

(2014) Norio Ozaki et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder

(2013) Chi-Un Pae et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Aripiprazole augmentation for major depressive disorder

(2013) Chi-Un Pae et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: A randomized, double-blind, placebo-controlled study (ADMIRE study)

(2013) Kunitoshi Kamijima et al.   JOURNAL OF AFFECTIVE DISORDERS

Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: A multi-center, naturalistic study

(2013) Changsu Han et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

(2011) Robert Berman et al.   Neuropsychiatric Disease and Treatment

The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder

(2009) Ronald N. Marcus et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY